Mortality in IPF (GAP Index)

Estimate mortality in idiopathic pulmonary fibrosis

About

This equation is taken from Ley et al (2012). The GAP Index was derived and validated based on 558 patients with idiopathic pulmonary fibrosis (IPF) from three academic centers in the United States and Italy. The GAP Index was validated at both presentation and during follow-up and can therefore be used throughout the disease course. Additional scoring systems have been developed in IPF, but are not validated, include more complex variables, or lack stage-specific management recommendations.

Clinical implications for the GAP Index were suggested by the authors as follows:

Stage 1:

  • Close monitoring (every 6 mo) for evidence of disease progression
  • Aggressive management of symptoms and comorbid conditions
  • May not require immediate listing for lung transplantation

Stage 2:

  • Close monitoring (every 3–6 mo) for evidence of disease progression
  • Consider listing for lung transplantation based on patient preferences, and evidence of disease progression

Stage 3:

  • Consider immediate listing for lung transplantation if appropriate or palliative care referral

References

Ley B et al.

Annals of Internal Medicine 2012 May 15, 156 (10): 684-91

T E King, J A Tooze, M I Schwarz, K R Brown, R M Cherniack

American Journal of Respiratory and Critical Care Medicine 2001 October 1, 164 (7): 1171-81

Wells AU et al.

American Journal of Respiratory and Critical Care Medicine 2003 April 1, 167 (7): 962-9

du Bois RM et al.

American Journal of Respiratory and Critical Care Medicine 2011 August 15, 184 (4): 459-66

The Mortality in IPF (GAP Index) calculator is created by QxMD.

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Gender?

0/4 completed